Bortezomib-inducible Long Non-coding RNA Myocardial Infarction Associated Transcript is an Oncogene in Multiple Myeloma That Suppresses MiR-29b

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2019 Apr 11

PMID 30967527

Citations 18

Authors

Yunfeng Fu

Xiao Liu

Fangrong Zhang

Siyi Jiang

Jing Liu

Yanwei Luo

Affiliations

Soon will be listed here.

Abstract

Clinical outcomes of patients with multiple myeloma (MM) have almost doubled the overall survival over the last decade owing to the use of proteasome inhibitor such as bortezomib (BTZ). However, some patients with MM develop primary resistance to BTZ, whereas others develop resistance after treatment. In this study, we investigated relationships between BTZ resistance and dysfunction of long non-coding RNAs (lncRNAs) in patients with MM. Bone marrow samples were collected from patients with MM and healthy donors for lncRNA microarray and survival analyses. To investigate functions and underlying mechanisms of lncRNA-mediated BTZ resistance in MM, we performed CCK-8 assays, flow cytometry analyses, dual luciferase report gene assays, and RNA pulldown assays with samples from nude mice carrying tumor xenografts and in clinical samples. Differentially expressed lncRNA myocardial infarction associated transcripts (MIAT) were highly expressed in patients with MM compared with healthy controls, and were predictive of poor survival outcomes. Moreover, MIAT expression was significantly increased in BTZ-resistant patients with MM compared with newly diagnosed patients with MM, and was identified as a BTZ-inducible lncRNA. Specifically, BTZ upregulated MIAT expression through increased stat1 phosphorylation. Silencing of MIAT inhibited MM cell growth and sensitized MM cells to BTZ by negatively regulating miR-29b. Our data demonstrated the utility of MIAT as a tool for overcoming BTZ resistance in patients with MM.

Citing Articles

Highlighting the role of long non-coding RNA (LncRNA) in multiple myeloma (MM) pathogenesis and response to therapy.

Al-Hawary S, Jasim S, Altalbawy F, Hjazi A, Jyothi S, Kumar A Med Oncol. 2024; 41(7):171.

PMID: 38849654 DOI: 10.1007/s12032-024-02392-8.

Targeting the long non-coding RNA MIAT for the treatment of fibroids in an animal model.

Chuang T, Ton N, Manrique N, Rysling S, Khorram O Clin Sci (Lond). 2024; 138(12):699-709.

PMID: 38817011 PMC: 11166562. DOI: 10.1042/CS20240190.

Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action.

Kulig P, Luczkowska K, Bakinowska E, Baumert B, Machalinski B Cancers (Basel). 2024; 16(1).

PMID: 38201512 PMC: 10778101. DOI: 10.3390/cancers16010084.

The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma.

Nylund P, Garrido-Zabala B, Kalushkova A, Wiklund H Front Oncol. 2023; 13:1303677.

PMID: 38148842 PMC: 10750364. DOI: 10.3389/fonc.2023.1303677.

High LYRM4-AS1 predicts poor prognosis in patients with glioma and correlates with immune infiltration.

Wang H, Xie Y, Du H, Luo B, Li Z PeerJ. 2023; 11:e16104.

PMID: 37810780 PMC: 10557942. DOI: 10.7717/peerj.16104.

References

Gandolfi S, Laubach J, Hideshima T, Chauhan D, Anderson K, Richardson P . The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017; 36(4):561-584. DOI: 10.1007/s10555-017-9707-8. View

de Oliveira M, Fook-Alves V, Eugenio A, Fernando R, Sanson L, de Carvalho M . Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients. Cancer Lett. 2017; 403:206-215. DOI: 10.1016/j.canlet.2017.06.016. View

Bai Q, Zhang X . Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-κB/JNK. Int J Mol Sci. 2012; 13(4):4831-4838. PMC: 3344248. DOI: 10.3390/ijms13044831. View

Jagannathan S, Vad N, Vallabhapurapu S, Anderson K, Driscoll J . MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. Leukemia. 2014; 29(3):727-38. PMC: 4360212. DOI: 10.1038/leu.2014.279. View

Ronchetti D, Agnelli L, Pietrelli A, Todoerti K, Manzoni M, Taiana E . A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma. Sci Rep. 2018; 8(1):6557. PMC: 5920050. DOI: 10.1038/s41598-018-24701-8. View

Li Y, Wang K, Wei Y, Yao Q, Zhang Q, Qu H . lncRNA-MIAT regulates cell biological behaviors in gastric cancer through a mechanism involving the miR-29a-3p/HDAC4 axis. Oncol Rep. 2017; 38(6):3465-3472. DOI: 10.3892/or.2017.6020. View

Mohan M, Matin A, Davies F . Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Manag Res. 2017; 9:51-63. PMC: 5338851. DOI: 10.2147/CMAR.S105163. View

Liu S, Wu L, Pang J, Santhanam R, Schwind S, Wu Y . Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010; 17(4):333-47. PMC: 2917066. DOI: 10.1016/j.ccr.2010.03.008. View

Amodio N, Rossi M, Raimondi L, Pitari M, Botta C, Tagliaferri P . miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget. 2015; 6(15):12837-61. PMC: 4536984. DOI: 10.18632/oncotarget.3805. View

10.

Fu Y, Li C, Luo Y, Li L, Liu J, Gui R . Silencing of Long Non-coding RNA MIAT Sensitizes Lung Cancer Cells to Gefitinib by Epigenetically Regulating miR-34a. Front Pharmacol. 2018; 9:82. PMC: 5816758. DOI: 10.3389/fphar.2018.00082. View

11.

Wu Y, Wang H . LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway. J Biochem Mol Toxicol. 2017; 32(1). DOI: 10.1002/jbt.22008. View

12.

Chen L, Hu N, Wang C, Zhao H, Gu Y . Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression. Cell Cycle. 2017; 17(3):319-329. PMC: 5914888. DOI: 10.1080/15384101.2017.1407893. View

13.

Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R . TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Cancer Sci. 2015; 106(4):438-46. PMC: 4409888. DOI: 10.1111/cas.12616. View

14.

Lai I, Yang C, Lin P, Chan W, Lee Y, Yen J . Long noncoding RNA MIAT promotes non-small cell lung cancer proliferation and metastasis through MMP9 activation. Oncotarget. 2017; 8(58):98148-98162. PMC: 5716720. DOI: 10.18632/oncotarget.21465. View

15.

Amodio N, Stamato M, Juli G, Morelli E, Fulciniti M, Manzoni M . Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018; 32(9):1948-1957. PMC: 6127082. DOI: 10.1038/s41375-018-0067-3. View

16.

Fuchs O . Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord Drug Targets. 2013; 13(1):16-34. DOI: 10.2174/1871529x11313010003. View

17.

Amodio N, Di Martino M, Foresta U, Leone E, Lionetti M, Leotta M . miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis. 2012; 3:e436. PMC: 3542610. DOI: 10.1038/cddis.2012.175. View

18.

Lipchick B, Fink E, Nikiforov M . Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res. 2016; 105:210-5. PMC: 5044866. DOI: 10.1016/j.phrs.2016.01.029. View

19.

Yan B, Yao J, Liu J, Li X, Wang X, Li Y . lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res. 2015; 116(7):1143-56. DOI: 10.1161/CIRCRESAHA.116.305510. View

20.

Tagoug I, Plesa A, Dumontet C . Bortezomib influences the expression of malignant plasma cells membrane antigens. Eur J Pharmacol. 2013; 706(1-3):11-6. DOI: 10.1016/j.ejphar.2013.02.002. View